Depreciation in USD of Lyra Therapeutics, Inc. from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Lyra Therapeutics, Inc. quarterly and annual Depreciation history and change rate from Q1 2019 to Q3 2025.
  • Lyra Therapeutics, Inc. Depreciation for the quarter ending 30 Sep 2025 was $100,000.
  • Lyra Therapeutics, Inc. annual Depreciation for 2024 was $471,000, a 69% increase from 2023.
  • Lyra Therapeutics, Inc. annual Depreciation for 2023 was $278,000, a 74% decline from 2022.
  • Lyra Therapeutics, Inc. annual Depreciation for 2022 was $1,067,000, a 6.6% increase from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Lyra Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $100,000 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $200,000 $0 0% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $128,000 -$8,000 -5.9% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q2 2024 $200,000 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $136,000 -$148,000 -52% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q1 2023 $1,071,000 $284,000 +$4,000 +1.4% 01 Jan 2023 31 Mar 2023 10-Q 30 Apr 2024 2024 Q1
Q4 2022 $1,067,000 $187,000 -$44,000 -19% 01 Oct 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
Q3 2022 $1,111,000 $300,000 -$100,000 -25% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $1,211,000 $300,000 $0 0% 01 Apr 2022 30 Jun 2022 10-Q/A 02 Nov 2022 2022 Q2
Q1 2022 $1,211,000 $280,000 +$210,000 +300% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $1,001,000 $231,000 +$190,000 +463% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $811,000 $400,000 +$367,000 +1112% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $444,000 $300,000 +$287,000 +2208% 01 Apr 2021 30 Jun 2021 10-Q/A 02 Nov 2022 2022 Q2
Q1 2021 $157,000 $70,000 +$62,000 +775% 01 Jan 2021 31 Mar 2021 10-Q/A 02 Nov 2022 2022 Q1
Q4 2020 $95,000 $41,000 +$34,000 +486% 01 Oct 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
Q3 2020 $61,000 $33,000 +$27,000 +450% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $34,000 $13,000 +$7,000 +117% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $27,000 $8,000 $0 0% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $27,000 $7,000 01 Oct 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
Q3 2019 $6,000 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $6,000 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $8,000 01 Jan 2019 31 Mar 2019 10-Q 28 May 2020 2020 Q1

Lyra Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $471,000 +$193,000 +69% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $278,000 -$789,000 -74% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $1,067,000 +$66,000 +6.6% 01 Jan 2022 31 Dec 2022 10-K 22 Mar 2024 2023 FY
2021 $1,001,000 +$906,000 +954% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $95,000 +$68,000 +252% 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
2019 $27,000 01 Jan 2019 31 Dec 2019 10-K 09 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.